Cargando…

Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia

Intensive chemotherapy directed against acute myeloid leukemia of childhood is followed by profound neutropenia and high risk for bacterial and fungal infections, including viridans group streptococci as a common cause for gram-positive septicemia. Few retrospective studies have shown the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Boztug, Heidrun, Mühlegger, Nora, Pötschger, Ulrike, Attarbaschi, Andishe, Peters, Christina, Mann, Georg, Dworzak, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225941/
https://www.ncbi.nlm.nih.gov/pubmed/27699447
http://dx.doi.org/10.1007/s00277-016-2833-5
_version_ 1782493603879190528
author Boztug, Heidrun
Mühlegger, Nora
Pötschger, Ulrike
Attarbaschi, Andishe
Peters, Christina
Mann, Georg
Dworzak, Michael
author_facet Boztug, Heidrun
Mühlegger, Nora
Pötschger, Ulrike
Attarbaschi, Andishe
Peters, Christina
Mann, Georg
Dworzak, Michael
author_sort Boztug, Heidrun
collection PubMed
description Intensive chemotherapy directed against acute myeloid leukemia of childhood is followed by profound neutropenia and high risk for bacterial and fungal infections, including viridans group streptococci as a common cause for gram-positive septicemia. Few retrospective studies have shown the efficacy of various antibiotic prophylactic regimens in children. We retrospectively studied 50 pediatric patients treated on the AML-BFM 2004 protocol between 2005 and 2015 at St. Anna Children’s Hospital and assessed the effect of antibiotic prophylaxis on the frequency of febrile neutropenia and bacterial sepsis. Fifty pediatric patients underwent 199 evaluable chemotherapy cycles. Viridans sepsis occurred after none of 98 cycles with prophylactic administration of teicoplanin/vancomycin in comparison to 12 cases of viridans sepsis among 79 cycles without systemic antibacterial prophylaxis (0 vs. 15 %, p < 0.0001). In addition, there were significantly fewer episodes of febrile neutropenia in the teicoplanin/vancomycin group (44 % vs. no prophylaxis 82 %, p < 0.0001). Severity of infection seemed to be worse when no antibiotic prophylaxis had been administered with a higher rate of intensive care unit treatment (0/98, 0 %, vs. 4/79, 5 %, p = 0.038). So far, no increase of vancomycin-resistant enterococcus isolates in surveillance cultures was noticed. Antibiotic prophylaxis with teicoplanin (or vancomycin) appears safe and feasible and resulted in eradication of viridans sepsis and decreased incidence of febrile neutropenia in pediatric AML patients. The possibility to administer teicoplanin on alternate days on an outpatient basis or at home could contribute to patient’s quality of life and decrease health care costs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00277-016-2833-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5225941
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-52259412017-01-24 Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia Boztug, Heidrun Mühlegger, Nora Pötschger, Ulrike Attarbaschi, Andishe Peters, Christina Mann, Georg Dworzak, Michael Ann Hematol Original Article Intensive chemotherapy directed against acute myeloid leukemia of childhood is followed by profound neutropenia and high risk for bacterial and fungal infections, including viridans group streptococci as a common cause for gram-positive septicemia. Few retrospective studies have shown the efficacy of various antibiotic prophylactic regimens in children. We retrospectively studied 50 pediatric patients treated on the AML-BFM 2004 protocol between 2005 and 2015 at St. Anna Children’s Hospital and assessed the effect of antibiotic prophylaxis on the frequency of febrile neutropenia and bacterial sepsis. Fifty pediatric patients underwent 199 evaluable chemotherapy cycles. Viridans sepsis occurred after none of 98 cycles with prophylactic administration of teicoplanin/vancomycin in comparison to 12 cases of viridans sepsis among 79 cycles without systemic antibacterial prophylaxis (0 vs. 15 %, p < 0.0001). In addition, there were significantly fewer episodes of febrile neutropenia in the teicoplanin/vancomycin group (44 % vs. no prophylaxis 82 %, p < 0.0001). Severity of infection seemed to be worse when no antibiotic prophylaxis had been administered with a higher rate of intensive care unit treatment (0/98, 0 %, vs. 4/79, 5 %, p = 0.038). So far, no increase of vancomycin-resistant enterococcus isolates in surveillance cultures was noticed. Antibiotic prophylaxis with teicoplanin (or vancomycin) appears safe and feasible and resulted in eradication of viridans sepsis and decreased incidence of febrile neutropenia in pediatric AML patients. The possibility to administer teicoplanin on alternate days on an outpatient basis or at home could contribute to patient’s quality of life and decrease health care costs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00277-016-2833-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-10-04 2017 /pmc/articles/PMC5225941/ /pubmed/27699447 http://dx.doi.org/10.1007/s00277-016-2833-5 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Boztug, Heidrun
Mühlegger, Nora
Pötschger, Ulrike
Attarbaschi, Andishe
Peters, Christina
Mann, Georg
Dworzak, Michael
Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia
title Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia
title_full Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia
title_fullStr Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia
title_full_unstemmed Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia
title_short Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia
title_sort antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225941/
https://www.ncbi.nlm.nih.gov/pubmed/27699447
http://dx.doi.org/10.1007/s00277-016-2833-5
work_keys_str_mv AT boztugheidrun antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia
AT muhleggernora antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia
AT potschgerulrike antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia
AT attarbaschiandishe antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia
AT peterschristina antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia
AT manngeorg antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia
AT dworzakmichael antibioticprophylaxiswithteicoplaninonalternatedaysreducesrateofviridanssepsisandfebrileneutropeniainpediatricpatientswithacutemyeloidleukemia